Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson’s disease, dystonia, and essential tremor are central nervous system conditions. What they have in common is the loss of sufficient, intact nervous system circuits that orchestrate functions as varied as memory formation (in Alzheimer’s) or voluntary motion (in movement disorders).



Scope of the Report:

This report studies the CNS Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the CNS Therapeutics market by product type and applications/end industries.

Mental health segment accounted for the largest market share in 2016. It is expected to retain its dominance over the forecast period owing to developing therapeutic options for mental diseases such as personality disorders and binge eating disorders. This segment is followed by degenerative disorders segment. There is growing awareness regarding neurodegenerative diseases owing to increase in initiatives by government and nongovernment organizations, such as Alzheimer’s and Related Disorders Society of India. These organizations conduct awareness campaigns and conferences, such as Asia Pacific Conference of ADI at New Delhi and Kerala State Initiative on Dementia, which encourage the adoption of treatment for degenerative and mental disorders.

The global CNS Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of CNS Therapeutics.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.



Market Segment by Companies, this report covers

Pfizer

Janssen Pharmaceuticals

Allergan

Lundbeck

Teva

Camber Pharmaceuticals

Zhejiang Haisen Pharmaceutical

Jewim Pharmaceutical

Cipla

Merck Sharp & Dohme Corp.

Eli Lilly

GlaxoSmithKline

Novartis

LUPIN

ZYDUS PHARMS

Biogen

Otsuka Pharmaceutical

Astra Zeneca

Shire



Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)



Market Segment by Type, covers

Neurodegenerative Diseases

Mood Disorders

Schizophrenia

Autism

Depression



Market Segment by Applications, can be divided into

Hospital Use

Clinic Use

Household

Other